A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs ALX 0171 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Acronyms Respire
  • Sponsors Ablynx
  • Most Recent Events

    • 24 Aug 2017 According to an Ablynx media release, the sequential dose escalation part of the has been completed in 36 infants hospitalised as a result of a respiratory syncytial virus (RSV) infection and the parallel dose part has been initiated subsequently with the aim to recruit an additional 144 infants, after a positive recommendation from the Data Monitoring Committee (DMC).
    • 24 Aug 2017 According to an Ablynx media release, topline results from the study are expected in the second half of 2018.
    • 11 Jan 2017 According to an Ablynx media release, top-line results from this trial are expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top